Stikbakke E, Richardsen E, Knutsen T, et al. - In the Prostate Cancer Study throughout Life, a prospective population-based cohort study of 7,356 men, to examine correlations between the inflammation-related biomarkers CRP and WBC and risk of prostate cancer development and severity, to ascertain whether markers of inflammation (WBC and high sensitivity-CRP, high sensitive[hs]-CRP) independently or in combination were correlated with risk and severity of prostate cancer, and to see the variation in CRP and risk of prostate cancer development and severity. A total of 509 men acquired prostate cancer during a mean 11.8 years follow-up. A positive dose-response association between hs-CRP and prostate cancer risk was found. In comparison with men with no difference or reduction in hsCRP, men with an improvement in hs-CRP among two measurements (Δhs-CRP) of ≥ 1.00 mg/L had a 36% heightened risk of prostate cancer. A 68% higher risk of being diagnosed with metastatic disease was observed in men with a systemic inflammatory score of 5 or 6, in contrast to men with lower scores. In conclusion, for prostate cancer risk and prognosis, hs-CRP comprising repeated measurements alone or in combination with WBC could be a beneficial inflammation-related biomarker.